Dendritic cell-based immunotherapy
TLDR
What has been learned thus far about human DC biology from clinical studies are discussed, and how current approaches to apply DC vaccines in the clinic could be improved to enhance anti-tumor immunity are discussed.Abstract:
Immunotherapy using dendritic cell (DC)-based vaccination is an approved approach for harnessing the potential of a patient's own immune system to eliminate tumor cells in metastatic hormone-refractory cancer. Overall, although many DC vaccines have been tested in the clinic and proven to be immunogenic, and in some cases associated with clinical outcome, there remains no consensus on how to manufacture DC vaccines. In this review we will discuss what has been learned thus far about human DC biology from clinical studies, and how current approaches to apply DC vaccines in the clinic could be improved to enhance anti-tumor immunity.read more
Citations
More filters
Journal ArticleDOI
Peptide-based assemblies as immune checkpoint inhibitor delivery systems for enhanced immunotherapy
TL;DR: This review introduces multiple types of immune checkpoints and peptide-based assemblies for immune checkpoint inhibitor delivery, and the roles of peptides in these assembles are described in detail.
Journal ArticleDOI
An Overview of the Recent Findings of Cell-based Therapies for the Treatment and Management of COVID-19
TL;DR: In this article, the authors compiled and summarized the immunopathogenesis of SARS-CoV-2 and the recent preclinical and clinical data on the potential of cell-based therapies in the fight against COVID-19.
Book ChapterDOI
Testing Cell-Based Immunotherapy for Colorectal Cancer
TL;DR: This work describes general validation steps for preclinical evaluation of cell-based immunotherapy and describes a xenograft model of human colorectal cancer that can be used for applied to pre clinical evaluation of various cell- based therapy regimens for coloreCTal cancer treatment.
Journal ArticleDOI
A Pan-Cancer Analysis of SLC12A5 Reveals Its Correlations with Tumor Immunity.
Yi Jiang,Hong-Li Liao,Li-Ya Chen +2 more
TL;DR: In this paper, Solute carrier family 12 member 5 (SLC12A5) has been reported to play an oncogenic role in certain malignancies and its prognostic roles and immune mechanisms of action in human cancers, however, remain largely unknown.
Journal ArticleDOI
Adenosine triphosphate, polymyxin B and B16 cell-derived immunization induce anticancer response.
Carlos Barrera-Avalos,Javier Mena,Ximena Lopez,Claudio Cappelli,Claudio Cappelli,Tanya Neira,Mónica Imarai,Ricardo Fernández,Claudia Robles-Planells,Leonel E. Rojo,Luis A. Milla,Elías Leiva-Salcedo,Alejandro Escobar,Claudio Acuña-Castillo +13 more
TL;DR: In this article, the authors used whole dead tumor cells as antigen source and the induction of a protective immune response could be enhanced by damage-associated molecular patterns by using B16-immunogenic cell bodies from B16 melanoma cells.
References
More filters
Journal ArticleDOI
Toll-like receptor signalling
Shizuo Akira,Kiyoshi Takeda +1 more
TL;DR: Rapid progress that has recently improved the understanding of the molecular mechanisms that mediate TLR signalling is reviewed.
Journal ArticleDOI
Immunobiology of Dendritic Cells
Jacques Banchereau,Francine Brière,Christophe Caux,Jean Davoust,Serge Lebecque,Yong-Jun Liu,Bali Pulendran,Karolina Palucka +7 more
TL;DR: Dendritic cells are antigen-presenting cells with a unique ability to induce primary immune responses and may be important for the induction of immunological tolerance, as well as for the regulation of the type of T cell-mediated immune response.
Journal ArticleDOI
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Naiyer A. Rizvi,Naiyer A. Rizvi,Matthew D. Hellmann,Matthew D. Hellmann,Alexandra Snyder,Alexandra Snyder,Pia Kvistborg,Vladimir Makarov,Jonathan J. Havel,William Lee,Jianda Yuan,Phillip Wong,Teresa S. Ho,Martin L. Miller,Natasha Rekhtman,Andre L. Moreira,Fawzia Ibrahim,Cameron Bruggeman,Billel Gasmi,Roberta Zappasodi,Yuka Maeda,Chris Sander,Edward B. Garon,Taha Merghoub,Jedd D. Wolchok,Jedd D. Wolchok,Ton N. Schumacher,Timothy A. Chan,Timothy A. Chan +28 more
TL;DR: Treatment efficacy was associated with a higher number of mutations in the tumors, and a tumor-specific T cell response paralleled tumor regression in one patient, suggesting that the genomic landscape of lung cancers shapes response to anti–PD-1 therapy.
Journal ArticleDOI
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Philip W. Kantoff,Celestia S. Higano,N. Shore,E. Roy Berger,Eric J. Small,David F. Penson,Charles H. Redfern,Anna C. Ferrari,Robert Dreicer,Robert B. Sims,Yi Xu,Mark W. Frohlich,Paul F. Schellhammer +12 more
TL;DR: The use of sipuleucel-T prolonged overall survival among men with metastatic castration-resistant prostate cancer and immune responses to the immunizing antigen were observed in patients who received sipuleUcel- T.
Journal ArticleDOI
Neoantigens in cancer immunotherapy
TL;DR: Observations indicate that neoantigen load may form a biomarker in cancer immunotherapy and provide an incentive for the development of novel therapeutic approaches that selectively enhance T cell reactivity against this class of antigens.
Related Papers (5)
Dendritic cells and the control of immunity
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more